Key Highlights

  • 156.3 million is the USD amount of cash, cash equivalents, and marketable securities that Larimar Therapeutics, Inc. (NASDAQ:LRMR) held on June 30, 2026, which management projects will fund operations into the third quarter of 2027.
  • 32.8 million is the USD net loss reported for the second quarter of 2026, or USD 0.30 per share, compared with a net loss of USD 26.2 million, or USD 0.41 per share, a year earlier.
  • 28.0 million is the USD Research and Development expense for the second quarter of 2026, up from USD 23.4 million, driven by Manufacturing qualification costs and higher clinical, data and BLA-related fees.
  • 2027 is the year management targets for a potential commercial launch of nomlabofusp, if approved, with the rolling BLA for Accelerated Approval expected to be completed in the second half of 2026.

What Investors Expect From Larimar Therapeutics, Inc. (NASDAQ:LRMR) on November 16, 2026

The clinical-stage company is scheduled to report third quarter 2026 results on November 16, 2026. The comparison point is the second quarter, when the net loss widened to USD 32.8 million from USD 26.2 million, an increase of about 25.2% calculated from those figures. Loss per share improved to USD 0.30 from USD 0.41 because the share count grew. For the six months ended June 30, 2026, the net loss was USD 62.4 million, or USD 0.61 per share, which averages USD 31.2 million per quarter, calculated.

The Rationale: Last Reported Quarter and Management Outlook for Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Research and development expense reached USD 28.0 million in the second quarter, against USD 23.4 million (up 19.7%, calculated), while general and administrative expense rose to USD 6.4 million from USD 4.4 million (up 45.5%, calculated), mainly on pre-launch commercial preparation. Six-month research and development expense was USD 53.0 million and general and administrative expense was USD 12.4 million. Management submitted the first module of a rolling BLA for nomlabofusp in June, expects to complete it in the second half of 2026, and expects first patient dosing in the global confirmatory Phase 3 study in the third quarter of 2026.

Valuation, Liquidity and Risks for Larimar Therapeutics, Inc. (NASDAQ:LRMR)

Liquidity of USD 156.3 million supports operations into the third quarter of 2027, and the company has not issued formal financial guidance beyond the runway projection and milestone timelines. Against a six-month loss of USD 62.4 million, the cash balance covers roughly 5 quarters of the first-half spending rate, calculated. Principal risks include regulatory review of the accelerated approval pathway, manufacturing qualification, the timing of Phase 3 enrollment, the potential need for additional Capital before a mid-2027 launch, and the binary nature of clinical and regulatory outcomes for a single lead program.

Where Things Stand

Larimar Therapeutics, Inc. (NASDAQ:LRMR) reports on November 16, 2026 with its lead program at the regulatory submission stage. At the end of June 2026 the company held USD 156.3 million of cash, had submitted the first BLA module for nomlabofusp and guided to a runway into the third quarter of 2027. Investors will look for progress on completing the rolling BLA, confirmation that the first patient has been dosed in the global confirmatory Phase 3 study, any refinement of the mid-2027 launch target, and updated spending, since research and development expense of USD 28.0 million and general and administrative expense of USD 6.4 million were the most recent quarterly levels.